Immunophotonics and Swiss Cancer Institute Complete SAKK 66/17 Phase 1b/2a Multicenter Clinical Trial for Treatment of Solid Tumors
ST. LOUIS, Aug. 21, 2025 /PRNewswire/ — Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel immune-stimulating drugs to augment... Read more.
Kinomica Expands IP Portfolio to 45 Granted Patents with New Assignments from QMUL, Strengthening Leadership in Phosphoproteomics
LONDON, Aug. 21, 2025 /PRNewswire/ — Kinomica Ltd., a clinical diagnostics company pioneering phosphoproteomic biomarkers to enable precision oncology, today... Read more.
Howmet Aerospace to Present at Jefferies Industrials Conference
PITTSBURGH, Aug. 21, 2025 /PRNewswire/ — Howmet Aerospace Inc. (NYSE: HWM) announced today that John C. Plant, Chairman and Chief Executive Officer will speak... Read more.
From “Market Blindness” to “Investor Magnet”: Korean PropTech Game Changer Wins Over 50 Clients Including GIC and DWS in Just 8 Months
SEOUL, South Korea, Aug. 21, 2025 /PRNewswire/ — Korean PropTech startup RSQUARE‘s RA (Rsquare Analytics) solution is reshaping how global investors... Read more.
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health
Company holds a dedicated meeting with Gates Foundation executives during Bill Gates’ visit to Korea. Both reviews expanded cooperation, including next-generation... Read more.
Hyundai Mobis acquires semiconductor development process certification for ISO 26262 ASIL-D
Received the highest grade for the entire R&D process, from design to quality verification Plans to mass-produce 20 million units of 16 major semiconductors... Read more.
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.... Read more.
UNIVERSITY RESEARCH PROGRAM NOW ACCEPTING RESEARCH PROPOSALS TO EMPOWER INNOVATION IN MATERIAL HANDLING
GREENE, N.Y., Aug. 21, 2025 /PRNewswire/ — The University Research Program is now accepting proposals through Oct. 31, 2025, for its next funding cycle. The... Read more.
Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award
CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ — Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism... Read more.
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H... Read more.